B+
Bull case
25%
Probability
Target price
$35.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
LEGN
Legend BiotechANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
CARVYKTI growth, broader global availability, and improving collaboration economics produced Legend's first profitable quarter, while the IMS evidence cycle and early LB2501 proof-of-concept offer additional clinical upside. Maintaining adjusted profitability through the second half would represent a material de-risking of the operating model.
Posture
Constructive
Lead driver
Sentiment
What changed
2 setup hits (3d) with net bearish as of 2026-09-12.
What can break
CARVYKTI carries serious safety risks including cytokine release syndrome, neurologic toxicities, cytopenias, infections, enterocolitis, and secondary malignancies; unfavorable real-world safety evidence could constrain earlier-line adoption.
Momentum
8
Value
41
Sentiment
100
Setup hits (3d)
2 · Net Bearish
AI TargetsBase $25.00 · Bull $35.00 · Bear $13.00Analysis 2026-09-12; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-12 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bearish
Target $46.89
Why
Momentum8 · Δ7d -4.5
Value41 · Δ7d -0.0
Sentiment100 · Δ7d +5.6
So what
Strength-led posture (Net Bearish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 2 setup hits (3d) with net bearish as of 2026-09-12.
- • Sentiment remains the lead driver in the composite, 7D delta +5.6.
Contradictions & invalidation
- • CARVYKTI carries serious safety risks including cytokine release syndrome, neurologic toxicities, cytopenias, infections, enterocolitis, and secondary malignancies; unfavorable real-world safety evidence could constrain earlier-line adoption.
- • Commercial and financial performance remains highly dependent on CARVYKTI and execution under the Janssen collaboration.
- • The thesis remains concentrated in one partnered franchise with serious labeled safety risks.
Catalyst clock
2026-09-25
September IMS data will test CARVYKTI durability and real-world safety
Lead driver: Sentiment · See AI snapshot
Momentum
8
9% active weight
Current posture
7d trendImproving
Δ7d
-4.5
Δ21d
+4.4
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
100
62% active weight
Current posture
7d trendImproving
Δ7d
+5.6
Δ21d
+10.9
Why this grade
Composite grade A. Momentum 7.9 / Value 41.2 / Sentiment 100.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-12. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$4B
Beta
0.11
Shares Out
193.77M
P/E (TTM) · Derived
-12.8
P/S (TTM)
4.13
P/FCF (TTM) · Derived
-14.57
Rev YoY
+51.6%
EPS YoY
-126.0%
Gross Margin
+53.0%
Op Margin
-4.1%
Net Debt
-$534.9M
Current Ratio
3.04
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data